Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCareSource Drug Formulary Update: Coverage & PA | …
    Ask Trek AI about this page
    CurrentCareSourcePolicy Formulary ID: 00026140, Version #: 9

    CareSource Dual Advantage Plus Formulary (Drug List)

    Customize your policy alerts

    Sign up for CareSource Policy Formulary ID: 00026140, Version #: 9 alerts

    Get alerted when Policy Formulary ID: 00026140, Version #: 9 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document is the plan formulary (Drug List) for CareSource Dual Advantage Plus (HMO D-SNP) current as of 04/01/2026 and details covered drugs, tiers, and restrictions (prior authorization, quantity limits, step therapy, mail-order, limited availability, non-extended day supply) for in-network pharmacies.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Policy Summary
    PayerCareSource
    PolicyCareSource Dual Advantage Plus Formulary (Drug List)
    Policy CodePolicy Formulary ID: 00026140, Version #: 9
    Change TypeFormulary update / clarifications (dates and requirement flags)
    Effective DateApr 1, 2026
    Last ReviewMar 13, 2026
    Next Review Date
    Key ActionObtain prior authorization for drugs marked 'PA' before dispensing; failure to obtain PA may result in non-coverage.
    SourceLink
    POLICY UPDATE CHANGES

    Formulary updated on 04/01/2026 and posted monthly; members notified of mid-year changes per Medicare rules.

    Multiple drug-tier and Requirements/Limits entries updated as of 03/13/2026.

    Drug list last updated on 03/13/2026 (noted multiple times).

    This part of the drug list indicates 'This drug list was last updated on 03/13/2026' multiple times.

    This part indicates the drug list was last updated on 03/13/2026.

    This drug list was last updated on 03/13/2026 and the overall formulary was updated on 04/01/2026.

    04/01/2026Last Updated
    00026140Formulary ID
    9Version
    In-network onlyNetwork
    manyPA entries
    multipleQL entries

    Coverage Summary

    Formulary Coverage Conditions and Exceptions

    Covered when ALL of the following are met:

    ALL of the following

    • Prescription is filled at a CareSource Dual Advantage Plus network pharmacy.
    • Drug is determined to be medically necessary for the member's condition by the prescriber.
    • Member and prescriber have met any applicable Formulary Requirements and Limits for the listed drug (see requirements and limits below).

      See 'Formulary Requirements and Limits (listing-level)' for specific codes and flags applied to individual formulary entries.

    • Coverage follows any active prior authorization, step therapy, and quantity limit rules applied to the drug.

    Exception (Formulary/Tiering/Restriction) Requests

    Exception requests are considered when the following conditions are met:

    ALL of the following

    • An exception request is submitted by the member or prescriber with supporting clinical information demonstrating medical necessity or why standard formulary requirements should be waived.
    • CareSource will decide standard (non-urgent) exception requests within 72 hours of receipt, and expedited (urgent) requests within 24 hours when the member's health could be seriously harmed by waiting for a standard decision.

      Expedited determinations apply when prescriber indicates that waiting 72 hours could seriously jeopardize the member's health or ability to regain maximum function.

    • If an exception is granted, coverage will be provided according to the approval terms (duration, quantity, renewal requirements).
    • Members may be eligible for interim coverage (see Temporary Coverage During Transitions) while exception requests are pending in certain circumstances.

    Temporary Coverage During Transitions

    Temporary coverage may be provided during transitions of care and when members are new to the plan under these conditions:

    ALL of the following

    • New members transitioning to CareSource who have an active prescription for a non-formulary or restricted drug may receive a one-time temporary supply to allow time for the member and prescriber to pursue a formulary alternative or exception request.

      Temporary supply periods and quantities depend on the situation described below.

    • Temporary supply rules

      • Standard transition supply: up to a 30-day supply of the current medication (or the equivalent), provided at a network pharmacy while the formulary exception or prior authorization is processed.
      • If the member’s prior plan allowed a 31-day supply and state law or contractual terms require it, a 31-day temporary supply may be permitted.

    Requirements & Limits (PA, QL, ST, NDS, LA)

    Requirements / Limits taxonomy

    Each drug entry includes one or more requirement/limit flags. Interpretation: coverage requires adherence to listed requirements/limits.

    Requirements / Limits taxonomy: PA (Prior Authorization) - coverage requires prior authorization when listed

    PA defined in table legend

    Requirements / Limits taxonomy: MO (Mail‑Order / Medical Override) - mail‑order availability or medical review/override handling when listed

    MO defined in table legend

    Requirements / Limits taxonomy: LA (Limited Access) - drug may be available only at certain pharmacies or limited distribution when listed

    LA defined in table legend

    Actions Required by Providers

    Prior Authorization

    Prior Authorization required for listed drugs

    Obtain prior authorization (PA) before dispensing any drug annotated with the PA requirement; failure to obtain PA may result in denial of coverage.

    • PA must be obtained prior to dispensing for drugs marked 'PA'.
    • Examples in formulary entries show many PA-flagged drugs (e.g., VOSEVI, CAYSTON, ADCETRIS).
    Documentation Required

    Exception requests require prescriber medical justification

    Exception (coverage/tiering restriction) requests must include a prescriber’s medical justification explaining why formulary alternatives or the restriction would be ineffective or harmful. Standard decisions are made within 72 hours of receiving the prescriber’s supporting statement; expedited (fast) decisions are available and must be decided within 24 hours if the prescriber indicates and the plan agrees the member could be seriously harmed by waiting.

    Applicable Codes & Formulary Abbreviations

    Formulary Abbreviations / Requirement Codesmixed
    PAPrior Authorization required
    QLQuantity Limit
    STStep Therapy required
    NDCNational Drug Code (product-specific)
    GCGeneric Common
    BRBrand
    OTCOver-the-Counter
    Example Drug Tier and Restrictions (selected entries)mixed
    ABIRATERONE 250 MGOral tablet; Tier and prior auth may apply
    ABIRATERONE 500 MGOral tablet; Tier and prior auth may apply
    ALECENSA 150 MGOral capsule; specialty tier likely; PA may apply
    ALUNBRIG ORAL TABLET 30 MGHigh-cost oncology agent; PA required
    ALUNBRIG ORAL TABLET 90 MGHigh-cost oncology agent; PA required
    ALUNBRIG ORAL TABLET 180 MGHigh-cost oncology agent; PA required
    ADSTILADRINIntravesical therapy; PA and site-of-care rules may apply
    AKEEGASpecialty oral; PA and QL may apply
    ADCETRISSpecialty injectable; PA required
    VIREAD ORAL TABLET 150 MGAntiviral; tiering applies
    1–10 of 14
    1/2
    Drug entries with PA requirementmixed
    CRESEMBA ORALPA required for most indications
    ABIRATERONE ORAL TABLET 250/500 MGPA required
    ALECENSAPA required
    ALUNBRIG (all strengths)PA required
    ADCETRISPA required
    ADSTILADRINPA required
    AKEEGAPA required
    BRADE/BLENREP/BRUKINSA (selected biologics)Specialty biologics — PA required
    DAPTOMYCIN INTRAVENOUS RECON SOLN 350 MGPA required for inpatient outpatient claim review
    DAPTOMYCIN INTRAVENOUS RECON SOLN 500 MGPA required
    1–10 of 13
    1/2
    Drugs with QL specifiedmixed
    XIFAXAN 550 MGQuantity Limit typically 2 tablets/day for hepatic encephalopathy; QL applies
    VIREAD (various strengths)Standard dispensing QL based on indication
    METHOTREXATE ORAL (oncology vs rheumatology)Different QLs by indication; prior auth may also be required
    Doxy-100Doxycycline 100 mg — standard QL applies
    SULFAMETHOXAZOLE-TRIMETHOPRIM IVQLs apply for inpatient/outpatient dosing
    VANCOMYCIN ORAL CAPSULE 125 MG/250 MGQLs may apply; separate IV formulations have separate QLs
    NDC-restricted productsNDC
    NDC: amphotericin b liposomeProduct-specific coverage; NDC-restricted; PA may apply
    NDC: CRESEMBA ORALNDC-level restrictions for oral formulations
    NDC: fluconazole in NaCl IV piggyback 200 mg/100 mlNDC-specific IV piggyback product; coverage restricted to specified NDCs
    NDC: valganciclovir oral recon solnNDC-specific; liquid reconstructions may be limited
    NDC: ceftazidime injection recon soln 1 gramNDC-restricted; PA/step and site-of-care rules may apply
    NDC: ceftazidime injection recon soln 2 gramNDC-restricted
    NDC: ceftazidime injection recon soln 6 gramNDC-restricted
    NDC: cefuroxime sodium injection recon soln 750 mgNDC-specific IV product restrictions
    NDC: cefuroxime sodium intravenous recon 7.5 gramNDC-specific
    NDC: cephalexin oral suspension for reconstitutionNDC-restricted pediatric formulations
    1–10 of 49
    1/5

    Background & Definitions

    This Drug List (formulary) is the CareSource Dual Advantage Plus (HMO D‑SNP) Drug List (Formulary) current as of 04/01/2026. It was developed with clinician consultation and lists the Part D covered drugs for the plan, organized by drug/treatment categories and an alphabetical index. The formulary shows each drug's plan tier and any utilization management controls that apply, including Prior Authorization (PA), Quantity Limits (QL), Step Therapy (ST), Mail‑Order (MO), Limited Access (LA), Non‑Extended Days' Supply (NDS), and B/D PA where a drug may be billed under Part B or Part D depending on setting.

    The Drug List explains how to find drugs (by medical condition grouping or the index), definitions for generics and biosimilars, and the meaning of the requirement/limit abbreviations shown on each drug row. It describes member protections and procedures for mid‑year formulary changes: immediate substitutions (for certain new generics/biosimilars), removals, or other changes follow Medicare rules and are posted monthly, and affected members will be notified at least 30 days before a change takes effect or may receive a 30‑day supply when requesting a refill.

    Members or prescribers may request exceptions (coverage, tiering, or to waive PA/QL/ST) by providing clinical justification. The plan generally decides standard exception requests within 72 hours of receiving the prescriber's supporting statement and provides expedited (24‑hour) review when waiting could seriously harm the member.

    The formulary emphasizes that drugs are covered when medically necessary, filled at a CareSource Dual Advantage Plus network pharmacy, and when listed requirements/limits are met; out‑of‑network fills may result in full member liability. The document and online postings (updated monthly) show the list of covered Part D drugs, tiers, and the specific requirement/limit flags for each product entry.

    TermDefinition
    PA
    Prior Authorization — plan requires approval before coverage
    QL
    Quantity Limit — plan limits the amount covered (numeric per time period)
    ST
    Step Therapy — required trial of specified drugs before others are covered
    MO
    Mail-Order Drug / Medical Override / Managed Option — available via mail order; may indicate medical necessity review (document uses MO)
    NDS
    Non-Extended Days' Supply — limited to 30-day supply at retail or mail-order
    LA
    Limited Availability — may be available only at certain pharmacies
    B/D PA
    May be covered under Part B or Part D depending on use/setting; information may be required
    V
    Vaccine — provided at no cost when used per ACIP (vaccine designation)

    Formulary Entries & Examples

    This part highlights representative, high‑impact formulary patterns and sample entries drawn from the indexed drug entries: specialty/high‑tier biologics and oncology agents with frequent PA/LA/NDS flags, vaccines and preservative‑free (PF) vaccine rows, insulin products and related devices (pens, pen needles, Omnipod entries), and multiple products showing QL numeric thresholds. The index also contains examples of NDC‑specific restrictions (e.g., albuterol HFA limited to listed NDC prefixes).

    The index and code groups include many individual drug/Tier/Requirements lines (examples shown in the formulary tables), but this section does not duplicate the full product list or page‑level coverage details. For full, page‑level coverage, exact QL values, NDC restrictions, and the complete Requirements/Limits columns, consult the full formulary pages and index referenced in the document.

    Vaccine / Miscellaneous entriesmixed
    GARDASIL 9 (PF)Tier 1; Requirements = V
    HEPLISAV-B (PF)Tier 1; Requirements = B/D PA; V
    HIBERIX (PF)Tier 3; Requirements = (V/none listed)
    VARIVAX (PF)Tier 1; Requirements = V
    VAQTA R SUSPENSION 50 UNIT/MLExample vaccine row with QL (1 per 720 days)
    Diabetes/insulin devices and productsmixed
    INSULIN products indexIncludes many insulin brands/formulations (LANTUS, HUMALOG, NOVOLIN, NOVOLOG, TOUJEO, LYUMJEV, FIASP) with MO, PA and QL flags
    PEN NEEDLE / OMNIPOD devicesDevice index lists OMNIPOD (GEN4/GEN5), PEN NEEDLES, insulin syringes
    GVOKE / GVOKE HYPOPENEmergency glucagon products listed; QL/ MO flags present
    High-impact specialty agents with PAmixed
    ENBREL SURECLICKQL (8 per 28 days); PA; MO; NDS
    XEMBIFYB/D PA; MO; LA; NDS (tier 5)
    INFLIXIMAB / REMICADEPA; MO; QL (20 per 28 days)
    SKYRIZI (IV)PA; MO; QL (30 per 180 days); NDS
    REPATHA / REPATHA SURECLICKPA; QL (6 per 28 days)

    FAQs

    Q: How do I request a formulary exception? A: You or your prescriber should contact the plan to request a tiering or coverage exception; the prescriber must explain the medical reasons why the exception is needed. The plan generally decides within 72 hours of receiving the prescriber's supporting statement; an expedited (fast) decision (within 24 hours) is available if the member’s health could be seriously harmed by waiting.

    Q: Will I get notice if my drug is removed mid‑year? A: When the plan makes mid‑year changes that affect members (removals, added restrictions, tier increases), affected members will be notified at least 30 days before the change becomes effective. Alternatively, when a member requests a refill they may receive a 30‑day supply of the drug and written notice of the change.

    Clinical Evidence / Rationale

    This Drug List / index is a formulary and navigation tool and does not present clinical trial or trial‑level evidence metrics. There are no trial‑level evidence items listed in this part; the document focuses on covered Part D products, tiers, and utilization management controls rather than primary clinical‑trial data.

    Revision History

    2026-04-01Formulary updatedLatest

    Formulary updated on 04/01/2026; updates are posted monthly to the plan website and reflected as current as of 04/01/2026.

    2026-03-13Part last updated

    This part of the drug list indicates the drug list was last updated on 03/13/2026; last updated date appears repeatedly with no other revision history in this part.

    mid-year (as needed)Mid-year changes / member notice
    Policy Summary
    PayerCareSource
    PolicyCareSource Dual Advantage Plus Formulary (Drug List)
    Policy CodePolicy Formulary ID: 00026140, Version #: 9
    Change TypeFormulary update / clarifications (dates and requirement flags)
    Effective DateApr 1, 2026
    Last ReviewMar 13, 2026
    Next Review Date
    Key ActionObtain prior authorization for drugs marked 'PA' before dispensing; failure to obtain PA may result in non-coverage.
    SourceLink
    On This Page
    Coverage SummaryRequirements & Limits (PA, QL, ST, NDS, LA)Actions Required by ProvidersApplicable Codes & Formulary AbbreviationsBackground & DefinitionsFormulary Entries & ExamplesFAQsClinical Evidence / RationaleRevision History
    Temporary coverage does not waive applicability of subsequent prior authorization, step therapy, or quantity limits after the temporary supply period ends; prescriber must complete any required requests to continue therapy.
  1. Transition supplies are intended to avoid gaps in therapy and are provided only once per drug per transition event unless otherwise permitted by plan policy or regulation.
  2. Requirements / Limits taxonomy: B/D PA - may be covered under Part B or Part D depending on use/setting; additional information may be required

    B/D PA explained in abbreviation list

    Requirements / Limits taxonomy: QL (Quantity Limit) - numeric limit per specified time window as shown in the Requirements/Limits column (e.g., 84 per 28 days)numeric per period

    QL numeric examples provided throughout the drug list

    Requirements / Limits taxonomy: NDS (Non‑Extended Days' Supply) - limited to 30‑day supply at retail or mail‑order when listed30 days

    NDS defined in table legend

    Formulary coverage requirements by drug/formulation

    Each listed drug/formulation is associated with specific requirement flags; coverage is conditional per those flags.

    Per‑product example: antiviral/infectious agents: MAVYRET oral tablet — Requirements/Limits = PA; MO; QL (84 per 28 days); NDSQL 84 per 28 days

    Example entry appears in drug table

    Per‑product example: antivirals/IV agents: Ganciclovir sodium IV recon soln — Requirements/Limits = PA; MO; QL (168 per 28 days); NDSQL 168 per 28 days

    Listed with B/D PA or PA depending on line

    Per‑product example: hepatic/antivirals: VOSEVI — Requirements/Limits = PA; MO; QL (28 per 28 days); NDSQL 28 per 28 days

    Shows how per‑product flags map to coverage conditions

    Per‑product example: inhaled/CF products: CAYSTON — Requirements/Limits = PA; MO; LA; QL (84 per 56 days); NDSQL 84 per 56 days

    Limited availability (LA) shown for some products

    Per‑product example: NDS and QL flags: Valganciclovir oral recon soln — Requirements/Limits = MO; NDS; Valacyclovir 1 g — Requirements/Limits = MO; QL (120 per 30 days)QL 120 per 30 days for valacyclovir

    Multiple entries illustrate mapping of flags to coverage

    • Prescriber must explain medical reasons why alternatives/restrictions are inappropriate.
    • Standard decision time: 72 hours; expedited decision time: 24 hours.
    Billing Rule

    Network pharmacy requirement

    Prescriptions must be filled at a CareSource Dual Advantage Plus network (in‑network) pharmacy for Part D coverage. If filled out-of-network, the member may be responsible for the full cost.

    • Network pharmacy required for prescription drug benefit.
    • Out-of-network fills may result in full member liability.
    Step Therapy

    Step therapy enforcement

    Follow step‑therapy (ST) requirements for drugs annotated 'ST' — the plan requires trial of specified first‑line agents before covering subsequent agents; document prior trials and clinical rationale when requesting overrides or exceptions.

    • ST requires trial of specified drugs before later agents are covered.
    • Document prior therapy and clinical rationale when requesting an exception or override.
    Documentation Required

    Specialty routing, NDC and NDS handling

    For NDS/LA/B/D PA and NDC‑restricted products, route specialty or limited‑availability drugs per plan instructions and bill using allowed NDCs. Drugs with NDS/LA or NDC‑only flags often require specialty pharmacy handling or specific NDC billing to receive the indicated coverage or tiering.

    • Some products list 'ONLY NDCS' or NDC ranges — bill with allowed NDCs to match coverage.
    • LA/NDS flags indicate limited distribution or specialty routing; follow plan specialty pharmacy rules.

    Describes immediate changes for generics/biosimilars, removals, and member notice/exception rights; when drugs are removed or restrictions added members are notified at least 30 days before the change or provided a 30-day supply at refill per Medicare rules.